Multiple Sclerosis Clinical Trial
Official title:
Intermittent vs. Continuous Walking Training in People With Multiple Sclerosis: a Comparison of Effectiveness
Verified date | May 2022 |
Source | Rutgers, The State University of New Jersey |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will compare the effectiveness of a traditional, continuous walking rehabilitation program for people with MS to the novel intervention of an intermittent or interval walking rehabilitation program. Half of the participants will receive the continuous walking program while the other half will receive the novel intermittent walking program.
Status | Suspended |
Enrollment | 24 |
Est. completion date | February 28, 2023 |
Est. primary completion date | February 28, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Self-identified difficulty walking - Definitive diagnosis of multiple sclerosis from a neurologist - Signed an approved consent form - Ability to ambulate for unaided for 6-minutes continuously with or without an assistive device (e.g. a cane or brace) - Has not had a multiple sclerosis relapse in the past 6 weeks Exclusion Criteria: - Unwilling or unable to complete assessments - Unwilling or able to complete assessments and or intervention without the use of portable functional electrical stimulation devices - Medical history of concomitant condition unrelated to multiple sclerosis which may impact results including: other neurological conditions including stroke, Parkinson's disease, or orthopedic, or cardiopulmonary conditions that affect walking - Had a major change in exercise habits in the past three months - Individuals reporting change in any disease modifying treatment or steroid use during the past 6 weeks - Unable to walk for 6 minutes continuously without physical assistance - Medical history of unstable angina, uncontrolled cardiac dysrhythmias causing symptoms, symptomatic severe aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus or pulmonary infarction, history of deep vein thrombosis, acute myocarditis or pericarditis, acute systemic infection, uncontrolled hypertension, and uncontrolled diabetes - Has an abnormal response to exercise - Cannot adhere to protocol - Determined to be unsafe at the discretion of the research team including individuals unwilling to wear safety "gait belt" during testing or not willing to wear proper footwear. |
Country | Name | City | State |
---|---|---|---|
United States | Mandell Center for Multiple Sclerosis - Mount Sinai Rehabilitation Hospital | Hartford | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Rutgers, The State University of New Jersey | City University of New York, School of Public Health, Mount Sinai Rehabilitation Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in 6-minute Walk Test distance | Is a measurement of the distance (in meters) walked at best pace in six minutes. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) | |
Secondary | Change in 12-item Multiple Sclerosis Walking Scale score | A survey that measures a participant's perception of how his/her walking ability is affected by multiple sclerosis. The scale ranges from 0-100 with lower scores representing a lesser impact of multiple sclerosis on the participant's walking ability. There are no subscales. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) | |
Secondary | Change in Fatigue Severity Scale score | A survey that measures a participant's perception of the impact of the symptom of fatigue on a person's ability to participate in life roles. The scale ranges from from 9-63, with lower scores representing a lower impact of fatigue on the ability to perform the activities listed in the scale.There are no subscales. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) | |
Secondary | Change in Step Length | The distance (in centimeters) traversed in one step from initial contact of one foot to the initial contact of the opposite foot. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) | |
Secondary | Change in Step Time | The time (in seconds) taken to complete one step from initial contact of one foot to the initial contact of the opposite foot. | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) | |
Secondary | Change in Stride Velocity | The speed with which it takes a person to complete one stride from initial contact of one foot to the next initial contact of the same foot | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) | |
Secondary | Change in Cadence | The number of steps (the initial contact of one foot to the initial contact of the opposite foot taken per minute | Baseline, 6 weeks (after intervention), and 12 weeks (6-week follow-up) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT02845635 -
MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis
|